AUPH · Aurinia Pharmaceuticals Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash flows from operating activities | $135.7M | twelve months ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AUPH
this stock
Aurinia Pharmaceuticals Inc.
|
$1.96B | -4.5% | +20.4% | 7.0 | 7.5% |
|
ONC
BeOne Medicines Ltd.
|
$472.27B | +7.6% | +22179.2% | 961.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$120.07B | +4.4% | +46.2% | 28.1 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.35B | -15.4% | +20.8% | 15.9 | 3.3% |
|
ARGX
Argenx SE
|
$57.84B | +9.9% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AUPH | -4.4% | -18.2% | +4.0% | -10.2% | -4.5% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -2.7% | -18.8% | -2.3% | -9.0% | -12.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.